XML 50 R39.htm IDEA: XBRL DOCUMENT v3.25.3

REVENUE AND DEFERRED REVENUE (Tables)

9 Months Ended

Sep. 30, 2025

REVENUE AND DEFERRED REVENUE

Schedule of percentages of deferred revenue by year

As of September 30, 2025, the Company expects to recognize approximately the following percentages of deferred revenue by year:

​

​	​	​	​
​		Revenue
Year:	​	Recognition
Remainder of 2025	​	46	%
2026		54	%
Total		100	%

Schedule of revenue generated in geographic regions for years indicated

​

​	​	​	​	​	​	​	​	​	​	​	​
​	​	Revenues by Geography
​	​	Three Months Ended September 30,
​	​	2025				​	2024
​	​	​	​	​	% of	​	​	​	​	% of
​	​	Amount		​	Revenues	​	Amount		​	Revenues
​	​	(in thousands, except percentages)									​
U.S.		$	36,248		97	%	$	17,922		97	%
International	​		1,049		3	%		608		3	%
Total revenues	​	$	37,297		100	%	$	18,530		100	%

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Revenues by Geography

​

​

​

Nine Months Ended September 30,

​

​

​

2025

​

2024

​

​

​

​

​

​

% of

​

​

​

​

% of

​

​

​

Amount

​

Revenues

​

Amount

​

Revenues

​

​

​

(in thousands, except percentages)

​

​

U.S.

$

105,387

98

%

$

50,845

97

%

​

International

​

1,993

2

%

1,552

3

%

​

Total revenues

​

$

107,380

100

%

$

52,397

100

%

​

U.S.

REVENUE AND DEFERRED REVENUE

Schedule of revenue generated in product category for years indicated

​

​	​	​	​	​	​	​	​	​	​	​	​
​	​	U.S. Revenues by Product Category
​	​	Three Months Ended September 30,
​	​	2025				​	2024
​	​	​	​	​	% of	​	​		​	% of
​		Amount			Revenues		Amount			Revenues
​		(in thousands, except percentages)									​
NeuroStar Advanced Therapy System	​	$	3,508	​	10	%	$	4,108	​	23	%
Treatment sessions	​		10,543		29	%		13,326		74	%
Clinic revenue	​	​	21,808	​	60	%	​	—	​	—	%
Other	​		389		1	%		488		3	%
Total U.S. revenues	​	$	36,248		100	%	$	17,922		100	%

​

​	​	​	​	​	​	​	​	​	​	​	​
​	​	U.S. Revenues by Product Category
​	​	Nine Months Ended September 30,
​	​	2025				​	2024
​	​	​	​	​	% of	​	​		​	% of
​		Amount			Revenues		Amount			Revenues
​		(in thousands, except percentages)									​
NeuroStar Advanced Therapy System	​	$	9,838	​	9	%	$	11,418	​	22	%
Treatment sessions	​		30,928		30	%		37,974		75	%
Clinic revenue	​	​	63,491	​	60	%	​	—	​	—	%
Other	​		1,130		1	%		1,453		3	%
Total U.S. revenues	​	$	105,387		100	%	$	50,845		100	%

International

REVENUE AND DEFERRED REVENUE

Schedule of revenue generated in product category for years indicated

​

​	​	​	​	​	​	​	​	​	​	​	​
​	​	International Revenues by Product Category
​	​	Three Months Ended September 30,
​	​	2025				​	2024
​	​	​	​	​	% of	​	​	​	​	% of
​		Amount			Revenues		Amount			Revenues
​		(in thousands, except percentages)									​
NeuroStar Advanced Therapy System	​	$	448		43	%	$	244		40	%
Treatment sessions	​		214		20	%		90		15	%
Other	​		387		37	%		274		45	%
Total international revenues	​	$	1,049		100	%	$	608		100	%

​

​	​	​	​	​	​	​	​	​	​	​	​
​	​	International Revenues by Product Category
​	​	Nine Months Ended September 30,
​	​	2025				​	2024
​	​	​	​	​	% of	​	​	​	​	% of
​		Amount			Revenues		Amount			Revenues
​		(in thousands, except percentages)									​
NeuroStar Advanced Therapy System	​	$	774		39	%	$	502		32	%
Treatment sessions	​		644		32	%		400		26	%
Other	​		575		29	%		650		42	%
Total international revenues	​	$	1,993		100	%	$	1,552		100	%

​

X

- Definition

Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

+ Details

Name:	us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of expected timing for satisfying remaining performance obligation.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(1)
-SubTopic 10
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingInformationLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: